AI assistant
Quoin Pharmaceuticals, Ltd. — Director's Dealing 2025
Aug 25, 2025
35443_dirs_2025-08-25_22300002-0c79-47bb-946b-791b0b56057e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2025-08-21
Reporting Person: Culverwell Anthony James (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-08-21 | Share Option (Right to Buy) | $9.07 | A | 13682 | Acquired | 2035-05-28 | ADS (13682) | Direct |
Footnotes
F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
F2: The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.
F3: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.